Literature summary for 3.4.22.B80 extracted from

Clemente, V.; DArcy, P.; Bazzaro, M.
Deubiquitinating enzymes in coronaviruses and possible therapeutic opportunities for COVID-19 (2020), Int. J. Mol. Sci., 21, 3492 .

Search for more literature for 3.4.22.B80

Application

Application	Comment	Organism
drug development	inhibitors of papain-like protease show promising results as an antiviral therapy in vitro. A list of inhibitors is reported that suggests possible therapeutic strategies for COVID-19 treatment, using both clinical and preclinical drugs	Severe acute respiratory syndrome coronavirus 2

Organism

Organism	UniProt	Comment	Textmining
Severe acute respiratory syndrome coronavirus 2	-	SARS-CoV-2	-

Synonyms

Synonyms	Comment	Organism
papain-like protease	-	Severe acute respiratory syndrome coronavirus 2
Plp	-	Severe acute respiratory syndrome coronavirus 2

General Information

General Information	Comment	Organism
physiological function	the enzyme has many roles in pathogenesis. First, it is one of the two viral cysteine proteases, that is responsible for the production of the replicase proteins required for viral replication. Second, its intrinsic deubiquitinating and deISGylating activities serve to antagonize the immune response that would otherwise hinder infection. Both deubiquitinating and deISGylating functions involve the removal of the small regulatory polypeptides, ubiquitin and ISG15, respectively, from target proteins. Ubiquitin modifications can regulate the innate immune response by affecting regulatory proteins, either by altering their stability via the ubiquitin proteasome pathway or by directly regulating their activity. ISG15 is a ubiquitin-like modifier with pleiotropic effects, typically expressed during the host cell immune response	Severe acute respiratory syndrome coronavirus 2

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)